Why J&J Is Poised to Outperform
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care products gorilla Johnson & Johnson has earned a coveted five-star ranking.
With that in mind, let's take a closer look at J&J and see what CAPS investors are saying about the stock right now.
New Brunswick, N.J. (1886)
Chairman/CEO Alex Gorsky
Return on Equity (average, past 3 years)
$19.8 billion / $16.9 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 14,045 members who have rated J&J believe the stock will outperform the S&P 500 going forward.
[J&J] has had some nice quarterly reports recently, looks undervalued by cash flow and seems to be in the midst of a successful turnaround. They are controlling costs and leveraging the firm's comparative advantage.
Of course, this short pitch doesn't even come close to telling the entire story of J&J. You're in luck, though. The Fool's brand new premium report on J&J tells all sides of the story for one of the most compelling blue chips in the market. You can grab your copy now, which comes with free updates for 12 months, by just clicking here.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why J&J Is Poised to Outperform originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.